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Abstract Glucocorticoid hormones, retinoids, and vitamin D3
display anti-angiogenic activity in tumor-bearing animals.
However, despite their in vivo effect on the tumor vasculature
little is known about their mechanism of action. Here we show
that the synthetic glucocorticoid dexamethasone (Dex) and
retinoic acid (RA) inhibit the activation of c-Jun N-terminal
kinase (JNK) and extracellular-regulated kinase (ERK) signal-
ling pathways by the pro-angiogenic agents tumor necrosis factor
and vascular endothelial growth factor in endothelial cells. In
contrast, Dex and RA failed to inhibit the activation of the p38
mitogen-activated protein kinase cascade. As a number of pro-
angiogenic factors activate AP-1 transcription factor via the
JNK and ERK pathways, our results suggest that the antagonism
with AP-1 may underlie at least partially the anti-angiogenic
effect of glucocorticoids and retinoids.
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1. Introduction
Angiogenesis, the formation of new blood vessels from pre-
existing ones, is a tightly regulated process whose contribution
to the development of a number of pathologies has been ex-
tensively documented [1,2]. The angiogenic process involves
several steps: degradation of the basal membrane, endothelial
cell chemotaxis towards inducers of angiogenesis and endo-
thelial cell proliferation [1]. This complex process is regulated
by an array of pro-angiogenic factors that stimulate angio-
genesis and of anti-angiogenic factors that halt angiogenesis
[1]. Interest in both types of factors arises from their potential
application as therapeutic agents for angiogenesis-dependent
diseases. In particular, much attention has focused on anti-
angiogenic factors as potential anti-tumor agents [3^5]. Both
anti-angiogenic and anti-tumor e¡ects have been described for
hormones acting through nuclear receptors such as glucocor-
ticoids [6^9], retinoic acid (RA) [10,11] and vitamin D3
(vitD3) [12,13]. These hormones exert their action through
binding to receptors that are hormone-regulated transcription
factors that may activate or repress gene expression [14]. A
large number of agents relevant for the angiogenic process
have been described to be regulated by nuclear hormones.
Among them are potent inducers of angiogenesis like vascular
endothelial growth factor (VEGF) [15,16] or moderate in-
ducers like transforming growth factor-L [17,18] or prosta-
glandin E2 [19]. Enzymes with a regulatory role in angiogen-
esis such as cyclooxygenases [20,21] or the inducible nitric
oxide synthase are regulated by glucocorticoids [22]. The tis-
sue- and urokinase-type plasminogen activator proteases are
regulated by RA [9,23^25]. Glucocorticoids, RA, and vitD3
also regulate the expression of several adhesion molecules that
may contribute to the angiogenic process: intracellular adhe-
sion molecule-1 [26], vascular cellular adhesion molecule-1
[27], E-selectin [28], L-selectin [29], tenascin [30], and E-cad-
herin [31]. In most cases expression of these molecules is re-
pressed by hormone-bound nuclear receptors. Repression of
gene transcription by nuclear hormone receptors is mainly
conducted either by binding to negative elements in target
genes or, more frequently, by interference with transcription
factors such as AP-1, NF-UB, or others [32]. The precise
mechanism of this antagonistic e¡ect has not been elucidated
yet. Protein-protein interactions or competition for co-activa-
tors such as the cyclic AMP response element binding protein
(CREB) binding protein (CBP) have been proposed, though
not convincingly demonstrated [32]. We and others have de-
scribed that nuclear hormone receptor antagonism with AP-1
in epithelial cells and macrophages is a consequence, at least
in part, of the inhibition of the c-Jun N-terminal kinase (JNK)
pathway by nuclear hormone receptors [33^36]. As a number
of pro-angiogenic factors act through activation of AP-1, we
sought to determine whether the anti-angiogenic e¡ect of glu-
cocorticoids, RA, or vitD3 may be mediated by the inhibition
of any of the signalling pathways leading to the activation of
members of the mitogen-activated protein kinase (MAPK)
family: JNK, extracellular-regulated kinase (ERK), and p38
mitogen-activated protein kinase (p38MAPK). We show here
that glucocorticoids and RA inhibit JNK activation by tumor
necrosis factor-K (TNFK) and also reduce ERK activation by
TNFK or VEGF in several endothelial cell lines. In contrast,
the activation of the p38MAPK cascade by di¡erent stimuli is
not a¡ected by these hormones.
2. Materials and methods
2.1. Materials
Dexamethasone (Dex), all-trans RA, phosphatase and protease in-
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hibitors (sodium pyrophosphate, sodium £uoride (NaF), L-glycero-
phosphate, sodium orthovanadate, phenylmethylsulfonyl £uoride
(PMSF), aprotinin, and leupeptin), myelin basic protein (MBP), pro-
tein A-Sepharose, and 12-O-tetradecanoyl phorbol 13-acetate (TPA)
were from Sigma Chemical Co. (St. Louis, MO, USA). TNFK and
VEGF were purchased from PeproTech Inc. (NJ, USA). VitD3 (1,25-
dihydroxyvitamin D3) was a kind gift from Productos Roche (Ma-
drid, Spain). Dulbecco’s modi¢ed Eagle’s medium (DMEM), fetal calf
serum (FCS), glutamine and antibiotics (penicillin, streptomycin) were
all from Life Technologies Ltd. (Paisley, UK). Autoradiography ¢lms
and the chemiluminescence ECL detection system were from Amer-
sham (London, UK).
2.2. Cell culture
The immortalized human microvascular endothelial cell line
HMEC-1 [37] was provided by Dr. T. Lawley (National Center for
Infectious Disease, Center for Disease Control, Atlanta, GA, USA),
and the murine microvascular MS-1 [38] and hemangioma-derived
EOMA [39] endothelial cell lines were provided by Dr. J. Folkman
(Harvard Medical School, Boston, MA, USA). All three cell lines, as
well as human cervical HeLa and mouse mammary epithelial EpH4
cells, were grown in DMEM supplemented with 10% FCS plus glu-
tamine and antibiotics.
2.3. RNA preparation and Northern analysis
Puri¢cation of poly(A) RNA, Northern blotting, and hybridiza-
tion were performed as described [40]. Filters were washed twice for
30 min each in 1% SDS and 40 mM sodium phosphate, pH 7.2 at
65‡C. Membranes were exposed to Hyper¢lm MP ¢lms. Densitomet-
ric analysis was performed in a La Cie scanner connected to a Power
Macintosh G3 computer using Adobe Photoshop 3.0 and NIH Image
programs. Probes used were a 1264 bp 3P fragment from the rat
glucocorticoid receptor (GR) cDNA donated by Dr. D. Barettino
(Instituto de Investigaciones Biome¤dicas, Valencia, Spain), the full-
length human retinoic acid receptor (RAR) K cDNA donated by
Dr. R.M. Evans (The Salk Institute, San Diego, CA, USA), and the
full-length human cDNA vitamin D3 receptor (VDR) donated by Dr.
M. Zenke (Max Delbru«ck Center, Berlin, Germany).
2.4. Protein kinase assays
For JNK and ERK assays subcon£uent endothelial cells (one p60
per determination) were preincubated overnight in DMEM supple-
mented with 0.5% FCS. Hormone treatments were carried out for
45 min before stimulation with 10 ng/ml TNFK or VEGF. At indi-
cated times after stimulation the cells were solubilized in NP40 lysis
bu¡er (1% NP40, 150 mM NaCl, 20 mM Tris-HCl pH 7.5, 2 mM
EDTA) supplemented with phosphatase inhibitors (10 mM sodium
pyrophosphate, 50 mM NaF, 25 mM L-glycerophosphate, 1 mM so-
dium orthovanadate) and protease inhibitors (1 mM PMSF and 10 Wg/
ml each of aprotinin and leupeptin). Lysates were cleared of insoluble
material by centrifugation and incubated for 2 h at 4‡C in the pres-
ence of 0.4 Wg/ml anti-ERK2 or anti-JNK1 antibodies (sc 154 and sc
474, Santa Cruz Biotechnology Inc.), followed by 1 h incubation at
4‡C with protein A beads. Immunoprecipitates were washed four
times with NP40 lysis bu¡er and once with kinase reaction bu¡er
(50 mM HEPES pH 7.5, 10 mM MgCl2, 12.5 mM L-glycerophos-
phate, 0.1 mM sodium orthovanadate). Samples were resuspended
in 40 Wl of kinase bu¡er containing 20 WM cold ATP and 1 WCi
Q-[32P]ATP. For ERK or JNK assays we used as substrates 10 Wg
MBP or 1 Wg of GST-c-Jun (1^79) protein, respectively. The reactions
were incubated at 30‡C for 30 min and terminated by addition of
5Uelectrophoresis sample bu¡er. Total amounts of JNK and ERK
were analyzed by Western blotting using the previously mentioned
anti-ERK2 or anti-JNK1 antibodies. Membranes were exposed to
Hyper¢lm MP ¢lms. Quantitation was performed as for Northern
blots.
For p38MAPK assays, cells were lysed in Triton bu¡er (1% Triton
X-100, 150 mM NaCl, 20 mM Tris-HCl pH 7.5, 2 mM EDTA) sup-
plemented with protease and phosphatase inhibitors as above. Kinase
activation was assessed by Western blot using an anti-phospho-spe-
ci¢c p38 antibody (9210, New England Biolabs). Membranes were
stripped and reprobed with an anti-p38MAPK antibody (sc 535, San-
ta Cruz Biotechnology Inc.) for loading control. Western blots were
developed using the ECL detection system and horseradish peroxi-
dase-conjugated anti-rabbit antibodies (55689, ICN).
3. Results
3.1. Expression of nuclear hormone receptors in endothelial cell
lines
We studied the expression of hormone receptors in human
HMEC-1, and murine EOMA and MS-1 endothelial cell lines,
to characterize their hormone responsiveness. The levels of
RNA expression of GR, RAR-K, and VDR were assessed
by Northern blotting. All three endothelial cell lines expressed
substantial levels of GR and RAR-K RNA, comparable to
those found in HeLa or EpH4 cells (Fig. 1). These two cell
types were chosen as controls in view of the previously de-
scribed hormone interference with AP-1 activation [31]. In
contrast, VDR RNA expression was only relevant in
HMEC-1 cells while it was undetectable in EOMA and
MS-1 lines. Consequently, we studied the e¡ects of Dex and
RA on the three MAPK signalling pathways: JNK, ERK,
and p38MAPK in all three endothelial cell lines, but that of
vitD3 exclusively in HMEC-1 cells.
3.2. Activation of the JNK pathway by TNFK in endothelial
cell lines is inhibited by glucocorticoids and retinoic acid
We ¢rst investigated the e¡ect of the synthetic glucocorti-
coid Dex and RA on the activation of JNK by TNFK. A
short (45 min) pretreatment with Dex led to an e⁄cient in-
hibition (3-fold) of JNK activation induced by TNFK in hu-
man HMEC-1 cells (Fig. 2A). In this same cell line RA also
had a less pronounced inhibitory e¡ect (Fig. 2B). Both hor-
mones, Dex and RA, similarly reduced JNK activation by
other stimuli such as ultraviolet radiation (data not shown).
The e¡ect of vitD3 was analogous to that of RA, leading to a
slight overall inhibition of JNK activation by TNFK in
HMEC-1 cells (Fig. 2B).
The inhibitory action of Dex on JNK activation by TNFK
was also found in EOMA and MS-1 endothelial cell lines (2^
3-fold) (Fig. 2C,D). In contrast, RA was less e¡ective in
EOMA and MS-1 cells as compared to human HMEC-1 cells
causing only a minimal inhibition of JNK activation (not
shown). This result correlated with the lower expression or
RARK RNA found in these rodent cell lines (Fig. 1).
As described previously in HeLa cells [33], the same inhib-
itory e¡ects were found by preincubation of HMEC-1 cells
with Dex or RA for longer periods of up to 18 h indicating
Fig. 1. Expression of GR, RARK, and VDR mRNA in HMEC-1,
EOMA, and MS-1 endothelial cell lines. Poly(A) RNA (10 Wg/
lane) was analyzed by Northern blot using speci¢c probes as de-
scribed in Section 2. RNA samples from human HeLa and mouse
EpH4 cells were included as controls. Filters were stripped and re-
hybridized with a cDNA probe of the 18S ribosomal RNA for load-
ing control. Sizes of corresponding bands are indicated.
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that a short incubation is su⁄cient for their maximal action
(not shown).
3.3. ERK activation by TNFK and VEGF is inhibited by
glucocorticoids in human endothelial cells
A number of pro-angiogenic factors like basic ¢broblast
growth factor, platelet-derived growth factor, TNFK, and
VEGF activate the ERK isoforms [41^43]. Moreover, induc-
tion of endothelial cell proliferation by VEGF requires ERK
activation [43], suggesting a relevant role of ERK signalling
cascade on angiogenesis. Therefore, we next investigated the
possibility of an antagonistic action of glucocorticoids on the
activation of ERK signalling pathways.
Dex inhibited (2^3-fold) ERK activation by TNFK or
VEGF in HMEC-1 cells (Fig. 3). Furthermore, ERK activa-
tion by serum and the phorbol ester TPA was also inhibited
by both Dex and, albeit to a lesser extent, RA (data not
shown).
3.4. Dexamethasone did not a¡ect p38MAPK activation
induced by TNAK
To complete the analysis of hormone e¡ects on MAPK
signalling pathways, we also examined the putative regulation
of p38MAPK activity. However, we found that Dex did not
inhibit p38MAPK activation induced by TNFK in HMEC-1
cells (Fig. 4). Likewise, Dex did not interfere with the activa-
tion of p38MAPK by other stress stimuli such as ultraviolet
radiation or osmotic shock caused by sorbitol or sodium
chloride in either HMEC-1 or HeLa cells (not shown). In
line with these results, RA and vitD3 also failed to inhibit
p38MAPK activation in HMEC-1 or HeLa cells (not shown).
4. Discussion
We present evidence that glucocorticoids and retinoids in-
hibit the activation of members of the MAPK signalling mod-
ules in endothelial cells. Inhibitory e¡ects of these hormones
on JNK activation by stress stimuli have been recently de-
Fig. 2. Activation of the JNK pathway by TNFK is inhibited by
Dex and RA. Cells were incubated in serum-free medium for 16 h
before addition of vehicle (3) or 1 WM Dex or RA as indicated.
After 45 min cells were stimulated with 10 ng/ml TNFK. JNK activ-
ity was measured in cell extracts prepared at indicated times after
TNFK treatment as described in Section 2. A: HMEC-1 cells, Dex
treatment. B: HMEC-1 cells, RA and vitD3 treatments. C: EOMA
cells, Dex treatment. D: MS-1 cells, Dex treatment. Quantitation of
the total amount of JNK protein present in each cell extract as esti-
mated by Western blotting is shown at the bottom of each panel.
Representative results corresponding to one out of three independ-
ent experiments are shown in each panel.
Fig. 3. ERK activation by TNFK or VEGF is inhibited by Dex in
HMEC-1 cells. Cells were incubated in serum-free medium for 16 h
before addition of vehicle (3) or 1 WM Dex as indicated. After 45
min cells were stimulated with 10 ng/ml TNFK or VEGF. ERK ac-
tivity was measured in cell extracts prepared at indicated times after
TNFK of VEGF treatment as described in Section 2. Bottom:
Quantitation of the total amount of ERK protein present in each
cell extract as estimated by Western blotting. Three independent ex-
periments gave similar results.
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scribed in epithelial (HeLa, EpH4, hepatocytes) and hemato-
poietic (macrophages) cells, suggesting that it is a wide mech-
anism of action for hormones acting through nuclear recep-
tors [33^36]. However, this is the ¢rst demonstration that
glucocorticoids and retinoids can inhibit JNK and ERK acti-
vation in endothelial cells by pro-angiogenic agents.
The precise mechanism by which hormone-activated nu-
clear receptors inhibit JNK or ERK activation is presently
unknown. Although a direct interaction of hormone receptors
with signalling elements in the JNK cascade (in the case of
GR) or with the kinases themselves cannot be ruled out, this
possibility has not been proved yet [33^36]. Alternatively, un-
characterized regulatory factor(s) could mediate the interfer-
ence with the JNK/ERK signalling modules upon hormone
binding to their receptors. Other possible mechanisms include
the activation of one or more protein phosphatases or the
blockade of the stimulus-induced nuclear translocation of
JNK/ERK.
While VEGF is considered to be a major pro-angiogenic
agent [1], TNFK seems to have a dual role in angiogenesis,
as a number of studies have proposed its role as a pro-angio-
genic factor [44,45], while others suggest an anti-angiogenic
role for this molecule [46,47]. Among other e¡ects, TNFK
induces the activation of AP-1 transcription factor through
the activation of JNK [48,49]. In contrast, VEGF preferen-
tially activates ERK and so, supposedly these two factors use
distinct signalling pathways to increase AP-1 activity. As in
other cell systems, the inhibitory e¡ect of Dex and RA on
JNK/ERK may at least in part underlie the antagonistic ef-
fects of these hormones on AP-1 activity. Given the roles of
VEGF and TNFK in the angiogenic process, our data suggest
that this antagonistic e¡ect can be part of the mechanism by
which several hormones with nuclear receptors behave as anti-
angiogenic agents in vivo.
Our results suggest that the inhibition of MAPK signalling
pathways is a general mechanism of hormone action which
shows a partial speci¢city, there being a preference for the
inhibition of certain signalling modules most probably de-
pending on the stimulus and cell type, amount of receptors
expressed, and perhaps interaction with other e¡ectors. Thus,
it has been reported that Dex does not block ERK activation
by LPS in macrophages [34], whereas RA inhibits growth
factor activation of ERK in normal human bronchial epithe-
lial cells [34]. Our data indicate that endothelial cells are sen-
sitive to Dex and RA inhibition of both JNK and ERK. In
contrast, p38MAPK activation by diverse stimuli appears to
be insensitive to these hormones in endothelial cells as well as
in other cell types.
Hormones with nuclear receptors such as glucocorticoids,
retinoids, and vitamin D3 are potent therapeutic agents and
have even been considered in some cases to be putative che-
mopreventive agents [50]. In the context of tumor angiogene-
sis the inhibition of MAPK signalling pathways is a potential
mechanism that would explain their anti-angiogenic e¡ect, for
instance by inhibiting the overexpression of genes encoding
proteases which become induced by pro-angiogenic factors
through AP-1-responsive sites in their promoter regions or
by modulating the expression of molecules regulating cell ad-
hesion and migration.
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